MRNS - Marinus Pharmaceuticals, Inc.
| Previous Close | 8.07 |
| Open | 8.04 |
| Bid | 7.25 x 1000 |
| Ask | 7.85 x 1000 |
| Day's Range | 7.65 - 8.21 |
| 52 Week Range | 1.66 - 9.87 |
| Volume | 476,497 |
| Avg. Volume | 742,003 |
| Market Cap | 311.604M |
| Beta | 3.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.68 |
| Earnings Date | Jul 30, 2018 - Aug 3, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.50 |
- ACCESSWIRE•5 days ago
Free Technical Research on Marinus Pharma and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on MRNS sign up now at www.wallstequities.com/registration. On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories.
- MarketWatch•9 days ago
Harry Boxer’s four health-care stocks to watch
In focus: Arbutus Biopharma, Marinus Pharmaceuticals, Neptune Technologies & Bioressources and OPKO Health.
- TheStreet.com•10 days ago
Pfizer Doesn't Look Fundamentally or Technically Strong
The best-looking trading group right now is the small oil stocks, but even those have thinned out after a few days of strong action. There are also a few biotech names making an effort to turn, but that's sparse, too. PFE also said that it's going to suspend drug-price increase that went into effect July 1 and will keep them on hold there until President Donald Trump unveils his plan to strengthen the U.S. health-care system.
- GlobeNewswire•24 days ago
Analysis: Positioning to Benefit within Marinus Pharmaceuticals, Valley National, BB&T, Cognizant Technology Solutions, Cinemark, and International Game Technology — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, June 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Marinus ...
- GlobeNewswire•last month
Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index
“We are pleased with Marinus’ addition to the Russell indexes,” said Christopher M. Cashman, Chief Executive Officer of Marinus. Russell US Indexes are the leading US equity benchmarks for institutional investors.
- GlobeNewswire•last month
Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder
Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the initiation of a pivotal Phase 3 clinical trial (Marigold Study) evaluating the use of oral ganaxolone in children and young adults with CDKL5 Deficiency Disorder (CDD). “We are excited to offer the CDKL5 patient community, for the first time, participation in a pivotal study of ganaxolone that may have the potential to reduce the seizure burden of the disorder,” said Christopher M. Cashman, Chief Executive Officer of Marinus.
- GlobeNewswire•last month
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 90,000 shares of its common stock to two new employees, with a grant date of June 14, 2018. The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.
- ACCESSWIRE•last month
Free Technical Reports on MannKind and Three Additional Biotech Equities
This morning, WallStEquities.com is focused on the Biotech space, which is engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Under evaluation today are these four equities: Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), MannKind Corp. (NASDAQ: MNKD), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT).
- Benzinga•last month
Marinus Pharmaceuticals Has 3 Major Catalysts In 2018, Ladenburg Thalmann Says In Bullish Initiation
Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) is a developer of ganaxolone, a therapy intended to treat patients with a rare genetic disorder, and initial data is "looking good," according to Ladenburg ...
- GlobeNewswire•2 months ago
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders. Ganaxolone is a positive allosteric modulator of GABAA that acts on a well-characterized target in the brain known to have both anti-seizure and anti-anxiety effects.
- ACCESSWIRE•2 months ago
Mayo Clinic-Backed NMTC Could Be Worth 3X This Year
For 1/3 of epilepsy patients, drugs won't control their seizures. Surgery may be an option (curative for some patients) but figuring out on what part of the brain to operate may require major brain surgery first: costly and invasive. This kind of event could put a lot of eyeballs on NMTC, and the stock has room to run as it goes through its first price discovery period.
- Motley Fool•2 months ago
Here's Why Marinus Pharmaceuticals Rose as Much as 18.4% Today
The tiny biopharma is back on the upswing following an analyst upgrade.
- Benzinga•2 months ago
Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 23) ABIOMED, Inc. (NASDAQ: ABMD ) ArQule, Inc. (NASDAQ: ARQL ) Crispr ...
- GlobeNewswire•2 months ago
Marinus Pharmaceuticals to Present at the UBS Global Healthcare Conference
Marinus Pharmaceuticals, Inc. (MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Christopher M. Cashman, Chief Executive Officer of Marinus, will present a company overview at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 10:00 a.m. ET. The conference will take place in New York. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.
- GlobeNewswire•2 months ago
Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology, McKesson, Marinus Pharmaceuticals, and Alnylam Pharmaceuticals — Fundamental Analysis, Key Performance Indications
NEW YORK, May 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of STORE ...
- Associated Press•3 months ago
Marinus Pharmaceuticals: 1Q Earnings Snapshot
The Radnor, Pennsylvania-based company said it had a loss of 15 cents per share. The company's shares closed at $4.50. A year ago, they were trading at $1.38. _____ This story was generated by Automated ...
- GlobeNewswire•3 months ago
Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results
Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the first quarter ended March 31, 2018. “Our team is laser-focused on enrolling our studies in women with postpartum depression and preparing the medical community for a soon-to-initiate global phase 3 pivotal study in children with CDKL5 deficiency disorder,” commented Christopher M. Cashman, chairman and chief executive officer of Marinus.
- Investor's Business Daily•5 months ago
Biotech Jumps After Rival Pushes Back Depression Drug Tests
Sage jumped Tuesday after rival Marinus said it would delay top-line results of a Phase 2 study in postpartum depression.
- Motley Fool•5 months ago
Here's Why Marinus Pharmaceuticals Dropped as Much as 17.7% Today
The biopharma's slide continues -- for good reason this time.
- Simply Wall St.•5 months ago
Is There Now An Opportunity In Marinus Pharmaceuticals Inc (NASDAQ:MRNS)?
Marinus Pharmaceuticals Inc (NASDAQ:MRNS), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqGM in the over the last fewRead More...
